Figure 2.

Southern blots from BV173 (a and b) and human primary progenitor cells (c–e) incubated with bioflavonoids, ascorbic acid, and VP16. Above and from left to right: no addition of drugs (−), DMSO control (C), chemotherapeutic drug VP16 (VP), bioflavonoids as indicated, fisetin (F), genistein (G), quercetin (Q), dietary quercetin-supplement (Q*), and ascorbic acid (Asc). Concentrations (μM) tested are indicated below. Germline (8.3 kb) and the cleavage fragments (7.0 kb and 1.3 kb) are indicated to the left with arrowheads. The FACS results at the time of drug treatment from umbilical cord blood (CB) or peripheral blood (PB) CD34⁺ ex vivo expansion into myeloid progenitor (prog) cells were (c) 20% CD33⁺/15⁺; 51% CD11b⁺/15⁺; 14% CD11b⁺/14⁺, and 15% propidium iodide⁺ (PI); (d) 36% CD33⁺/15⁺; 33% CD11b⁺/15⁺; 26% CD11b⁺/14⁺, and 5% PI⁺; (e) from umbilical cord blood T lymphocyte progenitor cells ex vivo expansion: 27% CD4⁺/8⁺; 44% CD4⁺; 19% CD8⁺, and 10% PI⁺.